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Appendix 1. Potential design and analytic solutions to selection bias, information bias, and confounding in cohort and case–control
studies evaluating drug–outcome associations
Type of Bias                                                                                           Potential Design or Analytic Solutions
Selection bias                                     - Use a population-based data source
(systematic error due to how                - Apply random sampling from the source population
patients are selected or maintained      - Adopt a well-codified accrual procedure
in the study)                                          - Select incident users of a medication when defining the cohort
                                                             - Minimize losses to follow-up and implement a tracking procedure for those who drop out
                                                             - Select incident cases for case–control study
Information bias                                 - Standardize measurement process
(systematic error due to                        - Use standardized definitions for exposure and outcome measurement
misclassification of exposure or            - Blind outcome assessors, especially for subjective outcomes
outcome status)                                    - Select data source with accurately measured exposures and outcomes (consult validity 
                                                             studies) 
Confounding                                      Design techniques:
(distortion or confusion of a                 - Restriction
drug–outcome association because      - Matching 
of one or more variables associated     - Active comparator
with the exposure and outcome of      Analytic techniques:
interest)                                                 - Direct or indirect standardization
                                                             - Stratification
                                                             - Multivariable regression modelling
                                                             - Propensity score adjustment
                                                             - Disease risk scores
                                                             - Instrumental variables
                                                             - Marginal structural models
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Appendix 2. Schematic showing origin of major biases in cohort studies
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Appendix 3. Common types of bias and confounding in cohort and case–control studies of drug effects
Type of Bias or Confounding                                                                            Mechanism of Bias
Selection bias
Referral bias                                          Occurs when the patients are referred to a health care provider or setting because of their 
                                                             drug exposure status.  
Self-selection (volunteer) bias                Occurs when patients decide to participate in or drop out of a study because of their drug 
                                                             status or health status.
Prevalence bias                                      In cohort studies, bias is introduced when prevalent drug users are studied because early 
                                                             outcome events are missed and certain confounders are improperly adjusted for. In case–
                                                             control studies, prevalent cases may be spuriously related to exposure because prevalence 
                                                             is proportional to the duration of disease.
Protopathic bias                                    Occurs when the first symptoms of the outcome of interest are the reasons for starting or 
                                                             stopping the exposure of interest.
Loss to follow-up bias                           Patients who do not respond or are lost to follow-up may introduce bias if their reason for 
                                                             nonresponse or loss to follow-up is related to their exposure and outcome status.
Immortal time bias                                Exclusion of the period of follow-up time whereby a patient cannot experience the outcome 
                                                             of interest (immortal time), which creates a false survival advantage to the exposed group.
Healthy user/adherer bias                      Occurs when patients who seek preventive therapy or are more adherent to therapy also 
                                                             participate in other preventive and health behaviours that are related to the outcome of 
                                                             interest.
Information bias
Exposure ascertainment bias                 Occurs when exposure status is misclassified because of errors in measurement. This may 
                                                             occur in cohort studies if exposure status is incorrectly measured because of missing 
                                                             information (e.g., only formulary medications captured) or because of how person-time is 
                                                             classified; specifically, misclassification of immortal time creates a false survival advantage 
                                                             for the exposed group.
                                                             In case–control studies, interviewers aware of a patient’s outcome status may change how 
                                                             they ascertain exposure status. Moreover, cases remember or forget exposure status more 
                                                             frequently than do controls.
Outcome ascertainment bias                Occurs when outcome status is misclassified because of errors in measurement. In cohort 
                                                             studies, information bias may occur if the procedure for detecting outcomes is related to 
                                                             the exposure status either via knowledge of exposure status or more intensive follow-up due 
                                                             to a certain drug exposure. 
